{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:13:00Z","timestamp":1791216780563,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,19]],"date-time":"2010-06-19T00:00:00Z","timestamp":1276905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s11906-010-0126-2","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T04:02:18Z","timestamp":1276833738000},"page":"252-257","source":"Crossref","is-referenced-by-count":62,"title":["Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome"],"prefix":"10.1007","volume":"12","author":[{"given":"Amir","family":"Tirosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail K.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,19]]},"reference":[{"key":"126_CR1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/diacare.28.2.385","volume":"28","author":"AM McNeill","year":"2005","unstructured":"McNeill AM, Rosamond WD, Girman CJ, et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care 2005, 28:385\u2013390.","journal-title":"Diabetes Care"},{"key":"126_CR2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-140-3-200402030-00007","volume":"140","author":"J Chen","year":"2004","unstructured":"Chen J, Muntner P, Hamm LL, et al.: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004, 140:167\u2013174.","journal-title":"Ann Intern Med"},{"key":"126_CR3","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1161\/CIRCULATIONAHA.105.539528","volume":"112","author":"PW Wilson","year":"2005","unstructured":"Wilson PW, D\u2019Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066\u20133072.","journal-title":"Circulation"},{"key":"126_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2009.10.042","volume":"210","author":"J Wang","year":"2010","unstructured":"Wang J, Sarnola K, Ruotsalainen S, et al.: The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis 2010, 210:237\u2013242.","journal-title":"Atherosclerosis"},{"key":"126_CR5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehl524","volume":"28","author":"J Wang","year":"2007","unstructured":"Wang J, Ruotsalainen S, Moilanen L, et al.: The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007, 28:857\u2013864.","journal-title":"Eur Heart J"},{"key":"126_CR6","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1001\/archinte.165.22.2644","volume":"165","author":"SG Wannamethee","year":"2005","unstructured":"Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005, 165:2644\u20132650.","journal-title":"Arch Intern Med"},{"key":"126_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.steroids.2008.10.010","volume":"74","author":"A Odermatt","year":"2009","unstructured":"Odermatt A, Atanasov AG: Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 2009, 74:163\u2013171.","journal-title":"Steroids"},{"key":"126_CR8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","volume":"308","author":"C Grossmann","year":"2009","unstructured":"Grossmann C, Gekle M: New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53\u201362.","journal-title":"Mol Cell Endocrinol"},{"key":"126_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cpcardiol.2008.10.002","volume":"34","author":"KK Gaddam","year":"2009","unstructured":"Gaddam KK, Pimenta E, Husain S, Calhoun DA: Aldosterone and cardiovascular disease. Curr Probl Cardiol 2009, 34:51\u201384.","journal-title":"Curr Probl Cardiol"},{"key":"126_CR10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","volume":"51","author":"NJ Brown","year":"2008","unstructured":"Brown NJ: Aldosterone and vascular inflammation. Hypertension 2008, 51:161\u2013167.","journal-title":"Hypertension"},{"key":"126_CR11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"JW Funder","year":"2009","unstructured":"Funder JW: Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009, 53:286\u2013290.","journal-title":"Hypertension"},{"key":"126_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","volume":"13","author":"JA Leopold","year":"2007","unstructured":"Leopold JA, Dam A, Maron BA, et al.: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189\u2013197.","journal-title":"Nat Med"},{"key":"126_CR13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, et al.: Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370\u20131376.","journal-title":"Nat Med"},{"key":"126_CR14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/CIRCRESAHA.109.196576","volume":"105","author":"CA Lemarie","year":"2009","unstructured":"Lemarie CA, Simeone SM, Nikonova A, et al.: Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009, 105:852\u2013859.","journal-title":"Circ Res"},{"key":"126_CR15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"126_CR16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"126_CR17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","volume":"54","author":"NC Edwards","year":"2009","unstructured":"Edwards NC, Steeds RP, Stewart PM, et al.: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54:505\u2013512.","journal-title":"J Am Coll Cardiol"},{"key":"126_CR18","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831\u20131838.","journal-title":"Circulation"},{"key":"126_CR19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, et al.: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641\u20132650.","journal-title":"J Am Soc Nephrol"},{"key":"126_CR20","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2007-1088","volume":"92","author":"R Bentley-Lewis","year":"2007","unstructured":"Bentley-Lewis R, Adler G, Perlstein T, et al.: Body Mass Index Predicts Aldosterone Production in Normotensive Adults on a High-Salt Diet. J Clin Endocrinol Metab 2007, 92:4472\u20134475.","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR21","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","volume":"21","author":"M Caprio","year":"2007","unstructured":"Caprio M, Feve B, Claes A, et al.: Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185\u20132194.","journal-title":"FASEB J"},{"key":"126_CR22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.beem.2005.07.002","volume":"19","author":"V Lamounier-Zepter","year":"2005","unstructured":"Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR: Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab 2005, 19:567\u2013575.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"126_CR23","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al.: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100:14211\u201314216.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"126_CR24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","volume":"60","author":"TL Goodfriend","year":"1999","unstructured":"Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401\u2013405.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"126_CR25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.0000154361.47683.d3","volume":"45","author":"S Engeli","year":"2005","unstructured":"Engeli S, Bohnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356\u2013362.","journal-title":"Hypertension"},{"issue":"Suppl 3","key":"126_CR26","first-page":"S61","volume":"24","author":"E Ferrannini","year":"1994","unstructured":"Ferrannini E, Seghieri G, Muscelli E: Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 1994, 24(Suppl 3):S61\u2013S69.","journal-title":"J Cardiovasc Pharmacol"},{"key":"126_CR27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00456122","volume":"29","author":"J Pierluissi","year":"1986","unstructured":"Pierluissi J, Navas FO, Ashcroft SJ: Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 1986, 29:119\u2013121.","journal-title":"Diabetologia"},{"key":"126_CR28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/HYPERTENSIONAHA.108.122002","volume":"53","author":"J Matrozova","year":"2009","unstructured":"Matrozova J, Steichen O, Amar L, et al.: Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009, 53:605\u2013610.","journal-title":"Hypertension"},{"key":"126_CR29","doi-asserted-by":"crossref","unstructured":"Catena C, Colussi G, Di Fabio A, et al.: Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010 Jan 29 (Epub ahead of print).","DOI":"10.1055\/s-0029-1246185"},{"key":"126_CR30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","volume":"16","author":"G Giacchetti","year":"2005","unstructured":"Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005, 16:120\u2013126.","journal-title":"Trends Endocrinol Metab"},{"key":"126_CR31","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, et al.: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457\u20133463.","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.amjhyper.2007.03.012","volume":"20","author":"F Fallo","year":"2007","unstructured":"\u2022 Fallo F, Della Mea P, Sonino N, et al.: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20:855\u2013861. Patients with primary aldosteronism had more insulin resistance (higher HOMA index) and lower levels of adiponectin than patients with low-renin essential hypertension in the absence of MetS.","journal-title":"Am J Hypertens"},{"key":"126_CR33","first-page":"21","volume":"108","author":"G Sindelka","year":"2000","unstructured":"Sindelka G, Widimsky J, Haas T, et al.: Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 2000, 108:21\u201325.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"126_CR34","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","volume":"95","author":"R Garg","year":"2010","unstructured":"\u2022\u2022 Garg R, Hurwitz S, Williams GH, et al.: Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010, 95:1986\u20131990. In normotensive healthy adults, high angiotensin II\u2013stimulated aldosterone level was an independent predictor of insulin resistance even after adjusting for age, body mass index, and diastolic blood pressure.","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR35","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/hrt.2009.173344","volume":"95","author":"EM Freel","year":"2009","unstructured":"Freel EM, Tsorlalis IK, Lewsey JD, et al.: Aldosterone status associated with insulin resistance in patients with heart failure\u2014data from the ALOFT study. Heart 2009, 95:1920\u20131924.","journal-title":"Heart"},{"key":"126_CR36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2009.06.030","volume":"407","author":"J Selvaraj","year":"2009","unstructured":"Selvaraj J, Muthusamy T, Srinivasan C, Balasubramanian K: Impact of excess aldosterone on glucose homeostasis in adult male rat. Clin Chim Acta 2009, 407:51\u201357.","journal-title":"Clin Chim Acta"},{"key":"126_CR37","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1210\/en.2008-0239","volume":"150","author":"JF Ndisang","year":"2009","unstructured":"Ndisang JF, Lane N, Jadhav A: The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 2009, 150:2098\u20132108.","journal-title":"Endocrinology"},{"key":"126_CR38","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","volume":"117","author":"C Guo","year":"2008","unstructured":"\u2022\u2022 Guo C, Ricchiuti V, Lian BQ, et al.: Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253\u20132261. In obese, db\/db mice, MR blockade reduced circulating triglyceride levels, decreased adipose tissue expression of inflammatory cytokines, and increased expression of adiponectin and PPAR\u03b3. In 3\u00a0T3-L1 preadipocytes, aldosterone increased expression of inflammatory cytokines and decreased expression of adiponectin and PPAR\u03b3, supporting a direct effect of aldosterone on gene expression.","journal-title":"Circulation"},{"key":"126_CR39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A Hirata","year":"2009","unstructured":"\u2022\u2022 Hirata A, Maeda N, Hiuge A, et al.: Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009, 84:164\u2013172. In obese, db\/db and ob\/ob mice, MR blockade reduced insulin resistance and improved adipose tissue inflammation (decreased reactive oxygen species and macrophage infiltration). In 3\u00a0T3-L1 adipocytes, aldosterone increased intracellular reactive oxygen species.","journal-title":"Cardiovasc Res"},{"key":"126_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0960-0760(03)00072-4","volume":"84","author":"C Calle","year":"2003","unstructured":"Calle C, Campion J, Garcia-Arencibia M, et al.: Transcriptional inhibition of the human insulin receptor gene by aldosterone. J Steroid Biochem Mol Biol 2003, 84:543\u2013553.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"126_CR41","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1210\/en.2008-1018","volume":"150","author":"T Wada","year":"2009","unstructured":"\u2022 Wada T, Ohshima S, Fujisawa E, et al.: Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3\u00a0T3-L1 adipocytes. Endocrinology 2009, 150:1662\u20131669. Aldosterone treatment in the adipocyte cell line resulted in IRS-1 serine phosphorylation and degradation, leading to decreased insulin stimulation of both Akt activation and glucose uptake. This mechanism was suggested to involve aldosterone-mediated intracellular oxidative stress.","journal-title":"Endocrinology"},{"key":"126_CR42","doi-asserted-by":"crossref","unstructured":"Sato A, Fukuda S: Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2009 Oct 29 (Epub ahead of print).","DOI":"10.1038\/jhh.2009.81"},{"key":"126_CR43","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","volume":"151","author":"T Wada","year":"2010","unstructured":"\u2022 Wada T, Kenmochi H, Miyashita Y, et al.: Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010, 151:2040\u20132049. MR blockade improved glucose metabolism (assessed by the glucose tolerance test and insulin tolerance test), reduced triglyceride and cholesterol levels, reduced hepatic inflammation (decreased hepatic expression of TNF\u03b1, interleukin-6, and MCP-1), and reduced hepatic steatosis in mice fed a high-fat and high-fructose diet.","journal-title":"Endocrinology"},{"key":"126_CR44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1751-7176.2009.00229.x","volume":"12","author":"B Kirilmaz","year":"2010","unstructured":"Kirilmaz B, Asgun F, Alioglu E, et al.: High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens (Greenwich) 2010, 12:136\u2013144.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"126_CR45","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","volume":"102","author":"M Caprio","year":"2008","unstructured":"Caprio M, Newfell BG, la Sala A, et al.: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008, 102:1359\u20131367.","journal-title":"Circ Res"},{"key":"126_CR46","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jcb.22352","volume":"108","author":"R Limor","year":"2009","unstructured":"\u2022\u2022 Limor R, Kaplan M, Sharon O, et al.: Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. J Cell Biochem 2009, 108:1203\u20131210. Treating vascular smooth muscle cells with aldosterone resulted in increased expression of 12- and 15-lipoxygenase expression and increased LDL oxidation. These effects were blocked by MR antagonists or an EGF-receptor antagonist, demonstrating potential interactions between these two receptors.","journal-title":"J Cell Biochem"},{"key":"126_CR47","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","volume":"92","author":"HV Joffe","year":"2007","unstructured":"Joffe HV, Kwong RY, Gerhard-Herman MD, et al.: Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552\u20132558.","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR48","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H Izawa","year":"2005","unstructured":"Izawa H, Murohara T, Nagata K, et al.: Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940\u20132945.","journal-title":"Circulation"},{"key":"126_CR49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","volume":"40","author":"AM Grandi","year":"2002","unstructured":"Grandi AM, Imperiale D, Santillo R, et al.: Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002, 40:647\u2013652.","journal-title":"Hypertension"},{"key":"126_CR50","first-page":"1477","volume":"363","author":"The NAVIGATOR Study Group","year":"2010","unstructured":"\u2022 The NAVIGATOR Study Group: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 363:1477\u20131490. In this large, placebo-controlled, randomized trial among patients with impaired glucose tolerance (many of whom met the MetS diagnostic criteria), the use of valsartan for 5\u00a0years led to a relative reduction of 14% in the incidence of diabetes. This study supports a role for blockade of the RAAS in preventing progression to diabetes.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0126-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-010-0126-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0126-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T19:37:50Z","timestamp":1635536270000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-010-0126-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,19]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1007\/s11906-010-0126-2","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,19]]}}}